Sodium Zirconium Cyclosilicate in Hyperkalemia

Packham, David; Rasmussen, Henrik; Lavin, Philip T.; El-Shahawy, Mohamed; Roger, Simon D.; Block, Geoffrey A.; Qunibi, Wajeh Y.; Pèrgola, Pablo E.; Singh, Bhupinder

doi:10.1056/nejmoa1411487

Cited by 433 publications

(486 citation statements)

References 25 publications

Supporting

Mentioning

430

Contrasting

Unclassified

Order By: Relevance

“…W przeglądzie systematycznym Cochrane [452] nie udokumentowano korzyści w znaczeniu poprawy rokowania po wdrożeniu żadnej z pilnych terapii obniżają-cych stężenie potasu. Dwie nowe substancje wiążące potas (patiromer i cyklokrzemian sodowocyrkonowy) są obecnie poddawane procesowi oficjalnego zatwierdzania [453,454]. Wstępne wyniki ich stosowania u pacjentów z HF i CKD wskazują na ich skuteczność w obniżeniu osoczowych stę-żeń potasu [455] oraz zapobieganiu nawrotu hiperkaliemii u pacjentów z HF i CKD w kontekście leczenie inhibitorami RAAS [456].…”

Section: Hipokaliemia I Hiperkaliemiaunclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

451

446

View full text Add to dashboard Cite

Section: Hipokaliemia I Hiperkaliemiaunclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

451

446

View full text Add to dashboard Cite

“…Furthermore, the predictors for long term mortality in survivors from index hyperkalemia have not been studied. Identification of these predictors will help to target high risk mortality groups with novel therapeutic agents [5,6].…”

Section: Discussionmentioning

confidence: 99%

“…The recent development of two new therapies to treat hyperkalemia, sodium zirconium cyclosilicate [5] which demonstrated significant reduction in potassium at 48 hours and maintenance of normokalemia during 12 days. Patiromer also showed a longer term decrease in serum potassium levels in 4 weeks and reduction in recurrence of hyperkalemia over subsequent 8 weeks [6].…”

Section: Introductionmentioning

confidence: 99%

Long-term Mortality Outcomes of Hyperkalemic Patients in the Emergency Department Setting: A Case Control Study

Velagapudi¹,

O’Horo²,

Glinskii³

et al. 2017

Arch Med

View full text Add to dashboard Cite

Background: The impact of an episode of hyperkalemia on long term mortality is not well studied. Such a study is vital for development of a utilization strategy for new drugs for the treatment of hyperkalemia. To study the long term impact of hyperkalemia on mortality, we conducted a retrospective, observational casecontrol study in a tertiary care emergency department. We compared cases of non-hemolyzed serum potassium >5.3 mEq/L with normokalemic controls. Allcause mortality and causes of death were determined from social security death index, national death index, and medical record review over a follow-up period of 490 patient years. Methods and Findings:A total of 287 consecutive subjects (223 cases, 64 controls) were identified among 14,483 patients. Cox proportional hazard regression showed that for each 1 mEq/L increase in admit potassium, all-cause mortality Hazard Ratio was 1.54, 95% Confidence Interval: 1.22-1.96. Subgroup analyses showed higher mortality in acute kidney injury and heart failure patients. Conclusion:Hyperkalemia predicted all-cause mortality, when adjusted for age, sex, Charlson comorbidity index, and significant covariates (heart failure and end stage renal disease). The deleterious effect of admit hyperkalemia persisted in survivors from index episode throughout the study period. Cardiovascular mortality was statistically more prevalent. Future studies are needed for risk stratification strategies and mortality impact of newer drugs.

show abstract

“…Hyperkalemia is not infrequent with RAS blockers and/or aldosterone antagonists treatment in such patients. The use of bisacodyl laxative [86] , patiromer, the nonabsorbed potassium binder [87] or sodium zirconium cyclosilicate [88] can control hyperkalemia. These agents are not associated with the potentially serious adverse effects of potassium exchange resins [89,90] .…”

Section: Pathogenesismentioning

confidence: 99%

Stop chronic kidney disease progression: Time is approaching

Din¹,

Salem²,

Abdulazim³

2016

WJN

View full text Add to dashboard Cite

Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has witnessed tremendous achievements in this field. Today we are optimistic; the dream of withholding this progression is about to be realistic. The recent discoveries in the field of CKD management involved most of the individual diseases leading the patients to end-stage renal disease. Most of these advances involved patients suffering diabetic kidney disease, chronic glomerulonephritis, polycystic kidney disease, renal amyloidosis and chronic tubulointerstitial disease. The chronic systemic inflammatory status and increased oxidative stress were also investigated. This inflammatory status influences the antisenescence Klotho gene expression. The role of Klotho in CKD progression together with its therapeutic value are explored. The role of gut as a major source of inflammation, the pathogenesis of intestinal mucosal barrier damage, the role of intestinal alkaline phosphatase and the dietary and therapeutic implications add a novel therapeutic tool to delay CKD progression.

show abstract

Sodium Zirconium Cyclosilicate in Hyperkalemia

Abstract: Patients with hyperkalemia who received ZS-9, as compared with those who received placebo, had a significant reduction in potassium levels at 48 hours, with normokalemia maintained during 12 days of maintenance therapy. (Funded by ZS Pharma; ClinicalTrials.gov number, NCT01737697.).

Cited by 433 publications

References 25 publications

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Long-term Mortality Outcomes of Hyperkalemic Patients in the Emergency Department Setting: A Case Control Study

Stop chronic kidney disease progression: Time is approaching

Contact Info

Product

Resources

About